Breaking News, Collaborations & Alliances

Oncternal, Pharmacyclics Enter Supply Agreement

Pharmacyclics to supply ibrutinib, a small molecule inhibitor of Bruton's tyrosine kinase (BTK), for a Phase 1b/2 trial

Oncternal Therapeutics announced a clinical supply arrangement with Pharmacyclics through which Pharmacyclics supplies ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), for a Phase 1b/2 clinical trial combining Oncternal’s novel monoclonal antibody, cirmtuzumab, and ibrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).  “What we’re looking to achieve in the treatment of B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters